Introduction
============

The Maghreb (region of Northwest Africa comprising five countries: Tunisia, Morocco, Algeria, Libya, and Mauritania) is undergoing an epidemiological transition characterized by a decrease of infectious diseases and an increase in chronic noninfectious ones.[@b1-dmso-5-227] This increase is largely due to a marked change in lifestyle (sedentary lifestyle, obesity, and stress of urbanization and labor), including changes in food consumption patterns.[@b1-dmso-5-227] Among noninfectious chronic diseases, non-insulin-dependent diabetes mellitus (NIDDM), a disease marked by expansion over the past decade, is becoming a real public health emergency.[@b2-dmso-5-227] For example, its prevalence in North Africa is estimated at 10%.[@b3-dmso-5-227] NIDDM poses a major public health problem, more particularly with the cardiovascular complications it causes (myocardial infarction \[MI\], occlusion of arteries of lower limbs, stroke).[@b1-dmso-5-227],[@b3-dmso-5-227]

To better explore this killer disease, it would be interesting to refer to the World Health Organization's latest classification of the natural history of chronic diseases, reporting three evolutionary stages:[@b4-dmso-5-227] deficiency, incapacity, and social disadvantage. The evaluation of incapacity (clinically characterized by dyspnea, pain in the lower limbs, and intermittent claudication[@b3-dmso-5-227],[@b5-dmso-5-227]) is considered essential, because alone it can predict the future functioning of the patient.[@b6-dmso-5-227] This is the determination of exercise tolerance through, for example, data from a field test such as the 6-minute walk test (6MWT), which explores the cardiorespiratory and muscle chain.[@b6-dmso-5-227] The social disadvantage is the psychosocial impact of the disease. This is the assessment of the quality of life (QOL).

Internationally, several recommendations for NIDDM management have been developed by scientific societies.[@b5-dmso-5-227],[@b7-dmso-5-227]--[@b11-dmso-5-227] These recommendations mainly focus on the exploration of deficiency (blood tests \[glucose, glycated hemoglobin {HbA~1c~}, lipid profile, microalbuminuria, renal function\], blood pressure). These explorations are conducted for static diagnostic purposes or to detect degenerative complications. However, none of these societies recommend the exploration of incapacity,[@b5-dmso-5-227],[@b7-dmso-5-227]--[@b11-dmso-5-227] while two recent studies[@b12-dmso-5-227],[@b13-dmso-5-227] have shown that NIDDM significantly alters submaximal aerobic capacity. These two studies unfortunately have methodological shortcomings: inclusion of patients with NIDDM and heart failure[@b13-dmso-5-227] or inclusion of only very elderly patients.[@b12-dmso-5-227]

The assessment of functional incapacity, for example, through 6MWT data (endurance test, intensity moderately higher than daily living activities[@b6-dmso-5-227],[@b14-dmso-5-227]), is desirable. Indeed, the skill of walking is a reflection of the ability to maintain a number of daily-life activities for patients.[@b6-dmso-5-227] Therefore, it is an important QOL component.[@b6-dmso-5-227]

Hence the aims of our study, done in NIDDM patients living in Northwest Africa, are:

1.  To estimate the incapacity of NIDDM patients by establishing their profile during the 6MWT: number of patients having an abnormal 6MWD, and/or stopping while walking, and/or having desaturation, and/or expressing dyspnea at the end of the test, and/or showing impaired chronotropic response.

2.  To determine factors influencing their 6MWD and to compare their chronological and estimated "cardiorespiratory and muscular chain" ages.

3.  To compare data of NIDDM patient group (PG; n = 100) with those of three control groups (CGs): CG1 (n = 174), healthy nonobese and nonsmoker; CG2 (n = 55), nondiabetic obese, free from comorbidities; CG3 (n = 59), nondiabetic "all comers."

Population and methods
======================

Study design
------------

We performed this cross-sectional study over a 5-month period in Farhat HACHED Hospital's Physiology and Functional Exploration Department and in the Basic Health Group's Laboratory of Biochemistry in Sousse (altitude \< 100 m), Tunisia.

Approval for the study was obtained from the hospital's ethics committee, and written consent was obtained from all study participants.

NIDDM patients were recruited in three ways. We contacted general practitioners and/or endocrinology specialists. An article was published in a weekly newspaper announcing the need for recruitment of NIDDM patients. Informational letters clarifying the aims of the study were then put up at the hospital and the local medical school.

NIDDM patient group
-------------------

Only patients aged over 40 years with an NIDDM status for more than 5 years were included. Noninclusion criteria were as follows: type 1 diabetes, insulin-requiring diabetes; history of orthopedic or surgical disease interfering with walking; recent infection; chronic corticoids use; inability to perform the 6MWT exactly and 6MWT counterindications;[@b6-dmso-5-227] unstable angina or myocardial infarction during the previous month; resting heart rate ≥ 120 bpm, resting systolic or diastolic pressure, ≥180 mmHg and ≥100 mmHg, respectively.

Sample sizes
------------

### NIDDM patient group

Sample size was calculated according to the following predictive equation:[@b15-dmso-5-227] n = (Z^2^ × p × q)/Δ^2^, where n was the number of required NIDDM patients, Z was the 95% confidence level (=1.96), q was equal to 1 -- p, Δ was the precision (=10%), and p was the estimation of the 6MWD decline or submaximal aerobic capacity induced by NIDDM. According to studies, 48% (*P* = 0.48) of older non-disabled diabetic patients at baseline developed functional limitations over a 7-year follow-up.[@b16-dmso-5-227] The sample size was thus 96.

### Control groups

We recruited three CGs over 40 years of age. They were tested in our department over the same period as the PG.

CG1: healthy nonobese and nonsmoker subjects (87 males and 87 females).

CG2: nondiabetic obese subjects free from comorbidities (17 males and 38 females).

These two CGs were recruited as a part of current protocols aiming to evaluate the submaximal exercise capacity of narghile smokers[@b17-dmso-5-227] and obstructive-sleep-apnea patients.[@b18-dmso-5-227]

CG3: Nondiabetic "all comers" subjects (37 males and 22 females) adressed to our department for 6MWT, indicated as preoperative assessment, or faced with various diseases (especially cardiorespiratory diseases).

Medical and physical activity questionnaires
--------------------------------------------

A medical questionnaire recommended for epidemiological research was used to assess subject characteristics (schooling level \[SL\] and occupational status, smoking, medical, surgical, and gynecologic-obstetric histories, and medication use).[@b19-dmso-5-227]

Two SLs were defined: low (illiterate, primary education) and high (secondary and university education). Two socioeconomic levels (SEL) were defined according to occupational status:[@b14-dmso-5-227] low (eg, unskilled worker, jobless) and high (eg, skilled worker, farmer, manager).

Cigarette and narghile usage was evaluated, respectively, in pack-years (PY) and narghile-years (NY).[@b20-dmso-5-227] Two groups of cigarette (0, no \[use \<2 PY\]; 1, yes \[use ≥2 PY\]) and narghile (0, no \[use \<1 NY), \]; 1, yes \[use ≥1 NY\]) users were defined. Narghile (water pipe that enables the smoking of a tobacco preparation burned by charcoal embers; the smoke is cooled by passing through water before being inhaled) use alters lung capacity and therefore cardiorespiratory fitness.[@b21-dmso-5-227],[@b22-dmso-5-227]

A translated version of the Voorrips[@b23-dmso-5-227] physical activity questionnaire was filled out by each subject, and household, sporting, and leisure activities were evaluated to yield a total physical activity score (low \< 9.4, moderate 9.4--16.5, and high \> 16.5).[@b23-dmso-5-227] According to the total physical activity score, two groups of subjects were defined, one as sedentary (score \< 9.4) and one as active (score \> 9.4).

Physical examination and parity
-------------------------------

Gender (0, male; 1, female) was noted and age (years) was verified by identity cards. Height (±0.01 m) was measured with a height gauge with shoes removed, heels joined, and back straight. Weight (±1 kg) was measured, and the body mass index (BMI, weight/height^2^, kg/m^2^) was calculated. The following definitions were adopted:[@b24-dmso-5-227] underweight (BMI \< 18.5), normal weight (BMI 18.5--24.9), overweight (BMI 25.0--29.9), and obese (BMI ≥ 30.0); with three classes: moderated (BMI 30.0--34.9), marked (BMI 35.0--39.9), and extreme (BMI ≥ 40.0). Two patient groups were defined (0, nonobese \[BMI \< 30\]; 1, obese \[BMI ≥ 30\]).

Parity referred to the number of offspring. Two parity subgroups were identified: low and high (parity \< 5 and ≥5, respectively).[@b14-dmso-5-227]

Electrocardiogram (ECG) and absolute cardiovascular disease risk (ACVDR) score
------------------------------------------------------------------------------

A 12-lead resting ECG was performed at baseline. Left ventricular hypertrophy was retained when the Sokolow--Lyon index was higher than 35 mm.[@b25-dmso-5-227] The ACVDR is the summation of the risk factors, each one being regarded as binary (present or absent) and having an identical weight ([Appendix Table 1](#t6-dmso-5-227){ref-type="table"}). An abnormal reading was not considered as a reason for excluding patients.

Metabolic data and definitions and diagnosis of NIDDM
-----------------------------------------------------

Glycemia (mmol/L), total cholesterol (mmol/L), and high-density-lipoprotein cholesterol (HDL-C, mmol/L) were quantified by spectrophotometry. Triglycerides (mmol/L) were quantified by the enzymatic colorimetric method. Low-density-lipoprotein cholesterol (LDL-C, mmol/L) was calculated.[@b26-dmso-5-227] HbA~1c~ (percentage) was quantified on hemolysed total blood (turbidimetric inhibition immunoassay).

NIDDM diagnosis was done according to international criteria:[@b27-dmso-5-227] clinical signs of diabetes and randomly measured glycemia ≥ 11.11 mmol/L or glycemia 2 hours after a caused oral hyperglycemia ≥ 11.11 mmol/L or a twice fasting glycemia ≥ 7.00 mmol/L.

The following metabolic definitions were applied. A rate of HbA~1c~ \> 7% shows an unbalanced NIDDM during the last 3 months,[@b9-dmso-5-227] and two groups of patients were identified (0, unbalanced; 1, balanced). Triglycerides ≥ 1.7 mmol/L and/or HDL-C \< 1 mmol/L and/or LDL-C ≥ 4.1 mmol/L diagnoses "measured" dyslipidemia,[@b26-dmso-5-227] and two groups of patients were defined (0, measured dyslipidemia; 1, no measured dyslipidemia).

6MWT procedure, dyspnea evaluation, applied definitions
-------------------------------------------------------

The 6MWT was conducted according to a standardized protocol.[@b6-dmso-5-227] The test was conducted along a seldom-traveled, flat, straight corridor (40 m long, marked every 1 m with cones to indicate turnaround points) with a hard surface. To minimize intraday variability, temperature effects, and biological rhythms, the 6MWT was performed between 8 am and 10 am, a period characterized by a stable ambient temperature of 16°C--20°C. All subjects performed the 6MWT for the first time with no warm-up period and no encouragement. Subjects were told to avoid vigorous exercise in the 2 hours prior to testing, to wear comfortable clothes and appropriate walking shoes, and to continue their usual medication.[@b6-dmso-5-227] The subjects sat in a chair located near the starting position for at least 10 minutes before the test started. During this time, dyspnea (visual analogue scale \[VAS\]), heart rate, and oxyhemoglobin saturation (oxy-sat) (finger pulse oximeter; Nonin Medical, Minneapolis, MN) and systolic and diastolic pressures (SP, DP, respectively) were measured at rest (~rest~). The test instructions to the subjects were those recommended by the American Thoracic Society.[@b6-dmso-5-227] At the end (~end~) of the 6MWT, the same data, in addition to 6MWD, were measured. Recommended reasons for immediately stopping the 6MWT include the following: chest pain, intolerable dyspnea, leg cramps, staggering, diaphoresis, and pale or ashen appearance.[@b6-dmso-5-227] In addition to 6MWD (m, %), dyspnea, SP and DP (mmHg), heart rate (bpm, % of predicted maximal heart rate \[= 208 -- 0.7 × age\]), oxy-sat, delta oxy-sat \[Δoxy-sat = oxy-sat{~rest--end~}\], and the number of stops during the 6MWT were noted/calculated. The 6MWD reference values were calculated according to local norms:[@b14-dmso-5-227] 6MWD (m) = 720.50 -- 160.27 × gender (0, male; 1, female) -- 5.14 × age (years) -- 2.23 × weight (kg) + 272.00 × height (m).

Since the 6MWT evaluates the integrated answer of the cardiorespiratory and muscular chain,[@b6-dmso-5-227] we calculated the "estimated age" of this chain:[@b14-dmso-5-227] estimated "cardiorespiratory and muscular chain" age (years) = 140.1751 -- 0.1945 × measured 6MWD (m) -- 31.1809 × gender (0, male; 1, female) -- 0.4338 × weight (kg) + 52.9183 × height (m).

Dyspnea during the 6MWT was evaluated by VAS, which allows an easy evaluation of exercise dyspnea.[@b28-dmso-5-227] It is about an open segment whose two ends are the absence of breathlessness and the maximum breathlessness. It was built on a slate for writing with dry erasable felt. Subjects read a standardized text in Arabic explaining dyspnea (or were read to, if they were illiterate) before each 6MWT. At the beginning and right at the end of the 6MWT, the subject indicated his level of breathlessness by marking with his index finger a vertical feature on the VAS. Dyspnea was then quantified from zero (no breathlessness) to ten (maximum of breathlessness).

The following definitions were applied:

-   A 6MWD lower than 82% was considered a "clinically significant abnormal value" and showed walk intolerance.[@b29-dmso-5-227]

-   Stopping during the 6MWT was regarded as an intolerance sign.[@b14-dmso-5-227]

-   A Δoxy-sat \> 5 points defines a "clinically significant desaturation."[@b14-dmso-5-227]

-   Any dyspnea~end~ \> 5/10 was considered as "clinically significant" and showed walk intolerance.[@b28-dmso-5-227]

-   A heart rate~end~ \< 60% was considered a chronotropic insufficiency.[@b14-dmso-5-227]

Study conduct
-------------

First visit (day 1): presentation of the patient to the Physiology Department, signature of consent, medical and physical activity questionnaires, anthropometric data, and baseline ECG.

Second visit (day 2): fasting blood sample, food intake (a cup of mineral water and some dates), VAS explanation; resting dyspnea, blood pressure, oxy-sat and heart rate, checks of the absence of 6MWT contraindications, 6MWT practice between 8 am and 10 am.

Data analysis
-------------

### Expression modes of results

The Kolmogorov--Smirnov test was used to analyse distribution of variables.[@b15-dmso-5-227] When the distribution is normal and the variances are equal, the results are expressed by their means ± standards deviations (SD). If the distribution isn't normal, the results are expressed by their medians (first--third quartiles). The chi-squared test was used to compare percentages.

### NIDDM PG: comparison of 6MWT measured data, univariate and multiple regression analysis (influencing factors)

The dependent variable (6MWD) was normally distributed. Student's *t*-test was used to compare measured versus theoretical 6MWD, resting versus 6MWT~end~ data, and to evaluate the associations between measured 6MWD (m) and categorical variables (0, no; 1, yes) for cigarette or narghile use, chronic respiratory disease, arterial hypertension, dyslipidemia, cardiovascular diseases, thyroid dysfunction, diabetic retinopathy, history of abdominopelvic and/or thoracic and/or neurological surgeries, beta-blocker or diuretic use, sedentary status, obesity group, diabetes balance, measured dyslipidemia, and left ventricular hypertrophy; (0, low; 1, high) for SEL, SL, parity, and (0, male; 1, female) for gender.

Pearson product-moment correlation (*r*) evaluated the associations between the measured 6MWD (m) and continuous measures (physical activity score, age \[years\], weight \[kg\], height \[m\], BMI \[kg/m^2^\], parity \[numerical\], fasting glycemia \[mmol/L\], HbA~1c~ \[%\], triglycerides \[mmol/L\], total cholesterol \[mmol/L\], HDL-C \[mmol/L\], LDL-C \[mmol/L\], ACVDR score, dyspnea~rest~, heart rate~rest~ \[bpm\], SP~rest~ \[mmHg\], DP~rest~ \[mmHg\], and oxy-sat~rest~ \[%\]). The linearity of the association between the 6MWD and the continuous measures was graphically checked by plotting each regressor against 6MWD. Only significantly and linearly associated variables were entered into the model.

A linear regression model was used to evaluate the independent variables explaining the variance in 6MWD. Candidate variables were stepped into the model with a stepwise selection method. To determine entry and removal from the model, significance levels of 0.15 and 0.05, respectively, were used. No colinearity between predictors was detected with variance inflation factors. The linear regression equation model is the following: 6MWD (m) = B~1~ × categorical variable~1~ + B~2~ × categorical variable~2~ + B~n~ × categorical variable~n~ + B**~×~**~1~ × continuous variable~1~ + B**~×~**~2~ × continuous variable~2~ + B**~×~**~n~ × continuous variable~n~ + constant. B is the nonstandardized regression coefficient.

### Comparison of NIDDM PG versus CG data

*t*-tests and chi-squared tests were used to compare quantitative data and percentages, respectively. In the same way, an analysis of variance was carried out between the four groups.

Analyses were carried out using Statistica software (Statistica Kernel version 6; StatSoft, Paris, France). Significance was set at the 0.05 level.

Results
=======

Patient group: noninclusion criteria, clinical, anthropometric, and metabolic characteristics
---------------------------------------------------------------------------------------------

An initial sample of 123 volunteer adults was examined. Noninclusion criteria, presented in detail in the [Appendix](#app1-dmso-5-227){ref-type="app"}, were found in 23 subjects.

[Table 1](#t1-dmso-5-227){ref-type="table"} exposes the clinical, anthropometric, and metabolic characteristics of the NIDDM PG. Compared to males, there are significantly fewer female cigarette or narghile users, more females having thyroid dysfunction or with surgical history, or having low SEL, SL, or having sedentary status, there are fewer overweight females, but a higher percentage of obese females. Compared to males, females have a significantly higher BMI and LDL-C level, a lower ACVDR score and are significantly shorter.

The 6MWD of the 45 females and 55 males, according to age-group, is shown in [Appendix Figure 1](#f1-dmso-5-227){ref-type="fig"}. Few older patients aged 65 years and more are included (four females and four males).

Additional information about the PG total sample characteristics are detailed in the [Appendix](#app1-dmso-5-227){ref-type="app"}.

PG: 6MWT data and profile
-------------------------

The 6MWT data are shown in [Table 2](#t2-dmso-5-227){ref-type="table"}. The total-sample measured 6MWD (566 ± 81 m) was significantly lower than the theoretical one (90% ± 12%). This difference of about 86 m was observed only in males. For females, males, and total sample, and compared to resting data, there was a significant increase in 6MWT~end~ SP, DP, and dyspnea. Oxy-sat significantly decreased only in males.

NIDDM patient profile during the 6MWT were as follows: 2% (1% females) stopped once during the 6MWT; 4% (2% females) showed a clinically significant desaturation; 12% (7% females) expressed a clinically significant dyspnea~end~; 21% (10% females) had a chronotropic insufficiency; and 23% (2% females) had an abnormal 6MWD.

PG: univariate and multiple regression analysis: influencing factors
--------------------------------------------------------------------

Gender significantly affected the 6MWD ([Table 2](#t2-dmso-5-227){ref-type="table"}). On average, the 6MWD values were 96 m greater (significant) in males when compared to females. This difference applies to patients aged between 45 and 60 years and more than 65 years ([Appendix Figure 1](#f1-dmso-5-227){ref-type="fig"}).

Univariate analysis between 6MWD and patient data is shown in the [Appendix Table 2](#t7-dmso-5-227){ref-type="table"}. In the total sample, the following categorical variables significantly affected the 6MWD: cigarette use, surgical history, SEL, SL, physical activity level, and obesity. In the total sample, 6MWD was significantly correlated (*P* \< 0.05) with the following continuous variables: age; height; BMI; daily, sporting, leisure, and physical activity scores; ACVDR score; SP~rest~; and oxy-sat~rest~. Several factors did not independently explain the variability of 6MWD, such as metabolic data.

[Table 3](#t3-dmso-5-227){ref-type="table"} presents the cumulative determination coefficient (*r*^2^) of the independent factors included in the 6MWD forward linear stepwise multiple regressions. For the total sample, gender, age, leisure activity score, obesity, SEL, cigarette use, and oxy-sat~rest~ were independent predictors, and up to 58% of the 6MWD variability could be explained with the proposed model in [Table 3](#t3-dmso-5-227){ref-type="table"}.

PG: "cardiorespiratory and muscular chain" estimated age
--------------------------------------------------------

In the total sample, the "cardiorespiratory and muscular chain" estimated age was significantly higher than the chronological age (68 ± 16 years versus 54 ± 8 years, respectively; *P* \< 0.05). This difference existed only in males (76 ± 13 years versus 54 ± 8 years, respectively; *P* \< 0.05).

PG: characteristics of patients distributed according to the 6MWD (normal versus abnormal 6MWD)
-----------------------------------------------------------------------------------------------

[Table 4](#t4-dmso-5-227){ref-type="table"} presents the characteristics of the two groups of patients with abnormal 6MWD (21 males, 2 females) and normal 6MWD (34 males, 43 females). Compared to the group having a normal 6MWD (94% ± 10%), the group having abnormal 6MWD (76% ± 5%), is significantly younger and taller, contains a significantly higher percentage of patients using cigarettes or having measured dyslipidemia, and has a higher ACVDR score.

PG: parity effect
-----------------

In the entire female population (n = 45), a negative univariate linear correlation was found between parity (numerical) and 6MWD (*r* = −0.44; *P* \< 0.05), and on average the 6MWD value was 61 m greater in females having low parity ([Appendix Table 2](#t7-dmso-5-227){ref-type="table"}). Parity also appeared to be a negative independent variable included in the forward linear stepwise multiple regression model for 6MWD ([Table 3](#t3-dmso-5-227){ref-type="table"}).

Comparison of NIDDM PG versus CG data
-------------------------------------

[Table 5](#t5-dmso-5-227){ref-type="table"} presents the characteristics of the PG and CGs. Analysis of the total samples 6MWDs revealed that compared to CG1 (636 ± 112 m, 100% ± 9%), to CG2 (100% ± 8%), and to CG3 (507 ± 129 m, 83% ± 14%), the PG (566 ± 81 m, 90% ± 12%) had a significantly lower 6MWD (m, %), lower 6MWD (%), and higher 6MWD (m, %), respectively. Detailed information appears in the [Appendix](#app1-dmso-5-227){ref-type="app"}.

Discussion
==========

The 6MWT profile of a large group of NIDDM patients older than 40 years was evaluated. It seems that NIDDM accelerates "cardiorespiratory and muscle chain" aging, with 23% of patients having an abnormal 6MWD. Impaired submaximal aerobic capacity is more pronounced in females and/or in the elderly and/or in subjects having low leisure activity score and/or in obese patients and/or in patients having low SEL and/or in cigarette smokers and/or in subjects having low resting oxy-sat. Compared to healthy nonobese and nonsmoking or nondiabetic obese control groups, NIDDM patients group had a significantly lower 6MWD.

Study design and statistical analysis
-------------------------------------

Detailed discussion of the recruitment method, the inclusion and noninclusion criteria, the sample size, and the questionnaires used appears in the [Appendix](#app1-dmso-5-227){ref-type="app"}. The number of measures and comparisons (n = 36) was too large for the number of participants included in the present study, usually one variable for ten participants.

Justification of the 6MWT choice to evaluate submaximal aerobic capacity
------------------------------------------------------------------------

Exercise tolerance is usually expressed in terms of maximal oxygen consumption (V̇O~2max~) measured during a cardiorespiratory test realized under optimal safety conditions and in the presence of a physician and a technician.[@b30-dmso-5-227] However, the cardiorespiratory test has some drawbacks. First, it uses expensive and sophisticated equipment, demanding that it be operated by highly qualified personnel.[@b6-dmso-5-227] Thus the repeated use of such a test for assessment of exercise training represents a significant financial cost.[@b6-dmso-5-227],[@b31-dmso-5-227] Second, the complexity of the examination and its interpretation does not allow the patient to have a quick and convenient representation of its progress.[@b6-dmso-5-227] Finally, this test can't be done on a large scale.[@b6-dmso-5-227] These drawbacks lead us to turn to the tests called "low-tech," such as the 6MWT (reliable, valid, safe, inexpensive, feasible on a large scale, can be performed by a physician, or a nurse, physiotherapist, or teacher of adapted physical activities). It is used to assess exercise tolerance not only of chronic respiratory diseases but also those with heart[@b32-dmso-5-227] or metabolic[@b12-dmso-5-227],[@b13-dmso-5-227] diseases. Another justification for our choice is that the 6MWT quantifies the ability to perform activities of daily life, familiar to subjects, and therefore supports the idea of submaximal activity. Finally, it is preferable to start as part of the assessment of exercise tolerance, by the practice of 6MWT and in case of an abnormal 6MWD, the cardiorespiratory test is largely indicated.[@b6-dmso-5-227]

Precautions taken during 6MWT
-----------------------------

The 6MWT was performed in the open air in a corridor of 40 m length.[@b6-dmso-5-227] Enright et al,[@b12-dmso-5-227] and Ingle et al,[@b13-dmso-5-227] used, respectively, corridors of 30 m and 15 m. Detailed discussion of the precautions taken during the 6MWT appears in the [Appendix](#app1-dmso-5-227){ref-type="app"}.

Characteristics of NIDDM PG
---------------------------

Our NIDDM sample can be considered as representative of the Northwest African population with NIDDM. Indeed, in our study, the frequency of risk factors and certain comorbidities observed were similar to those reported in other studies ([Appendix Table 3](#t8-dmso-5-227){ref-type="table"}).

Limitations of this study
-------------------------

In females, menopause and changes in hormonal status that may affect aerobic capacity[@b33-dmso-5-227] haven't been evaluated. Passive smoking has not been studied despite its adverse effects on exercise capacity, particularly as it reduces the lungs' performance.[@b34-dmso-5-227] We didn't measure quadriceps strength or the leg length, known as 6MWD-influencing factors.[@b29-dmso-5-227] In this study, we evaluated NIDDM patient deficiency by determining fasting glycemia, HbA~1c~, lipid profile, blood pressure, and ACVDR score. However, there are other biological markers such as oxidative stress, inflammation, and apoptosis,[@b35-dmso-5-227]--[@b40-dmso-5-227] which may cause disabilities through myopathy.[@b41-dmso-5-227] Similarly, it was desirable to measure some morphological data (lower-limb length,[@b29-dmso-5-227] muscle biopsy data,[@b41-dmso-5-227] or lung function[@b42-dmso-5-227]). As part of exploration of incapacity, it was desirable to achieve in a number of our patients a cardiorespiratory test and to evaluate the correlation between V̇O~2\ max~ and 6MWD. As part of the exploration of social disadvantage, it was desirable to explore the QOL of our patients. However, to our knowledge, there is no validated Arabic version of the QOL questionnaire specific to NIDDM patients.[@b43-dmso-5-227]

Deterioration of submaximal aerobic capacity
--------------------------------------------

Submaximal aerobic capacity of NIDDM patients seems to have deteriorated. Indeed, the measured 6MWD was 86 m less than the predicted one. In addition, almost one-quarter of our NIDDM patients had an abnormal 6MWD. Similarly, there were signs of walking intolerance (2% and 12% of patients stopped the walk and expressed a clinically significant dyspnea~end~, respectively). Finally, compared to healthy nonobese, nonsmokers and nondiabetic obese CGs, the PG had a significantly lower 6MWD.

Another key outcome of the present study is that the NIDDM accelerates the "cardiorespiratory and muscle chain" aging. It is an unwavering argument to motivate patients to better compliance with preventive and therapeutic measures. To our knowledge, this result has never been shown before.

Twenty-one percent of our patients had an impaired chronotropic heart response. This reflects the impact of NIDDM on the activity of the sinus node during the walk.[@b44-dmso-5-227] Moreover, the ACVDR score of the group with abnormal 6MWD was significantly higher than the group with normal 6MWD ([Table 4](#t4-dmso-5-227){ref-type="table"}). This is an important argument to encourage patients with NIDDM to start regular exercise.[@b45-dmso-5-227] Indeed, the exercise training and aerobic capacity were positively related to cardiovascular profile.[@b45-dmso-5-227]

To our knowledge, only two studies have examined the submaximal aerobic capacity of NIDDM patients.[@b12-dmso-5-227],[@b13-dmso-5-227] The first study, conducted in 2003 by Enright et al,[@b12-dmso-5-227] aimed to establish 6MWD norms specific to the US population aged 68 years and more (n = 2117 subjects, 13% had NIDDM). The multiple linear regression model revealed that the NIDDM was an independent predictor that altered the 6MWD.[@b12-dmso-5-227] These authors recommended the 6MWT to assess the impact of NIDDM and other comorbidities (cardiovascular or respiratory diseases, arthritis, cognitive dysfunction, depression, etc) on elderly submaximal aerobic capacity.[@b12-dmso-5-227] The second study, a retrospective one, conducted in 2006 by Ingle et al,[@b13-dmso-5-227] compared the 6MWD of four matched groups of patients (no statistical difference in age or gender): "heart failure with NIDDM" (n = 88) versus "heart failure free from NIDDM" (n = 88), "coronary artery disease with NIDDM" (n = 50) versus "coronary heart disease free from heart failure" (n = 50). These authors found that the 6MWD of the "heart failure with NIDDM" group (238 ± 124 m) was significantly lower than the 6MWD of the "heart failure free from NIDDM" (296 ± 131 m) and that the 6MWD of the "heart failure free from NIDDM" group (231 ± 139 m) was significantly lower than the 6MWD of the "coronary heart disease free from heart failure" group (283 ± 126 m).[@b13-dmso-5-227] These authors found that NIDDM was an independent determinant of low submaximal aerobic capacity.[@b13-dmso-5-227]

How can we explain the impairment of submaximal aerobic capacity of NIDDM patients?
-----------------------------------------------------------------------------------

The first important point of the present study is that classical biological data (fasting glycemia, HbA~1c~, lipid) often used to monitor the development of NIDDM don't appear as indicators of incapacity ([Table 3](#t3-dmso-5-227){ref-type="table"} and [Appendix Table 2](#t7-dmso-5-227){ref-type="table"}). However, there is evidence that regular physical activity in NIDDM patients is associated with a significant improvement in glycemic control, particularly in HbA~1c~.[@b45-dmso-5-227] Moreover, evaluation of NIDDM patient physical training programs is mainly based on the HbA~1c~ changes.[@b46-dmso-5-227]--[@b49-dmso-5-227]

In the total sample ([Table 5](#t5-dmso-5-227){ref-type="table"}), the alteration of submaximal aerobic capacity is more pronounced in females and/or in the elderly and/or in subjects having a low leisure activity score and/or in obese patients and/or in patients having low socioeconomic level and/or in cigarette smokers and/or in subjects having low oxy-sat~rest~. It is important to note that the suppression of the eight patients aged 65 years and more doesn't significantly confound the total sample actual results. These factors, in addition to parity, will be analyzed one by one in the following sections.

### Effect of gender

As in some healthy[@b14-dmso-5-227],[@b29-dmso-5-227] or patient[@b12-dmso-5-227] adult populations, we found that females compared to males have a lower 6MWD ([Table 3](#t3-dmso-5-227){ref-type="table"} and [Appendix Table 2](#t7-dmso-5-227){ref-type="table"}). One plausible explanation is that muscle mass and therefore maximum leg-muscle force is lower for females than males.[@b50-dmso-5-227] Another plausible explanation is parity, known as a physiological factor, accelerating the healthy female's 6MWD decline.[@b14-dmso-5-227] Indeed, among NIDDM females, in addition to age and SEL, parity appears to be an independent factor influencing 6MWD ([Table 3](#t3-dmso-5-227){ref-type="table"}). Among healthy women aged more than 40 years, the 6MWD decreased by 9.58 m when parity increased by one unit (*r* = −0.39, *P* \< 0.05).[@b14-dmso-5-227] In our study, NIDDM accelerated this decline, since the 6MWD of NIDDM female subjects decreased by 13.38 m when parity increased by one unit (*r* = −0.44, *P* \< 0.05).

### Effect of age

As in most studies of healthy[@b14-dmso-5-227],[@b29-dmso-5-227] or patient[@b51-dmso-5-227] adult populations, we found that age is a predictor of 6MWD decline. The potential physical decrease observed with aging is partly due to reduced muscle mass, strength, and endurance, thus defining sarcopenia.[@b14-dmso-5-227] Indeed, from 40 years of age, muscle mass decreases by an average of 5% per decade.[@b50-dmso-5-227]

### Effect of physical inactivity

Physical inactivity significantly influences healthy subjects' 6MWD, which decreased by 2.30 m when the physical activity score decreased by one point.[@b25-dmso-5-227] This decrease was more pronounced in NIDDM patients,[@b52-dmso-5-227] since patients with low leisure-activity scores (sedentary status) had a lower 6MWD by of 7.33 m ([Table 3](#t3-dmso-5-227){ref-type="table"}). This result is an important argument to encourage NIDDM patients to start regular exercise.[@b40-dmso-5-227]

### Effect of obesity

Obesity, especially the marked type, is predictive of 6MWD decline.[@b6-dmso-5-227],[@b29-dmso-5-227] Indeed, some authors[@b14-dmso-5-227] have shown that healthy subjects' 6MWD decreases by about 6 m when the BMI increases by one unit. In our study, being obese reduced 6MWD by 35.57 m ([Table 3](#t3-dmso-5-227){ref-type="table"}). This confirms once more the adverse effects of obesity on aerobic capacity,[@b6-dmso-5-227] and suggests that the obesity--NIDDM association accelerates 6MWD decline. This result is an important argument to encourage NIDDM patients to start a diet and/or regular exercise.[@b47-dmso-5-227]

### Effect of SEL

In a healthy Tunisian population, the SEL significantly influenced the 6MWD.[@b14-dmso-5-227] Indeed, having a low SEL decreases the 6MWD by 12.78 m.[@b14-dmso-5-227] Our study suggests that the onset of NIDDM in subjects having a low SEL accelerates the 6MWD decline since it reaches 32.86 m ([Table 3](#t3-dmso-5-227){ref-type="table"}).

### Effect of smoking

It is well known that smoking causes aerobic capacity alteration.[@b53-dmso-5-227] In our study, being a cigarette smoker decreased 6MWD by 27.67 m ([Table 3](#t3-dmso-5-227){ref-type="table"}), and the group with abnormal 6MWD had a significantly higher percentage of cigarette smokers ([Table 4](#t4-dmso-5-227){ref-type="table"}). This result, which confirms once again the harmful effects of smoking,[@b54-dmso-5-227] is a very important point to encourage NIDDM patients to stop smoking.

### Effect of resting oxy-sat

In our study, the greater the oxy-sat~rest~ was, the greater the 6MWD was ([Table 5](#t5-dmso-5-227){ref-type="table"}). In many chronic diseases, desaturation during a walk is an independent prognostic marker and is associated with a significant risk of mortality.[@b55-dmso-5-227],[@b56-dmso-5-227] For example, in pulmonary arterial hypertension, desaturation of more than 10% increased the mortality risk by 2.9.[@b56-dmso-5-227] In NIDDM, the clinically significant desaturation observed in 4% of our nonsmoking patients free from chronic respiratory diseases can be explained by the impact of diabetes on lung function[@b42-dmso-5-227] with impaired alveolar--capillary membrane.[@b42-dmso-5-227]

### Effect of parity

6MWD was lower by 61 m in NIDDM females with high parity ([Appendix Table 2](#t7-dmso-5-227){ref-type="table"}). This result may be clinically relevant when interpreting 6MWT in females with NIDDM. A simple way to solve this problem would be to substract 61 m from the theoretical value of these females. This phenomenon may reflect the general findings about aging and parity effects on health.[@b57-dmso-5-227] In fact, repeated gestations have been found to have potentially noxious effects on health, and several hypotheses, discussed in a previous paper,[@b14-dmso-5-227] have been advanced (detailed discussion appears in the [Appendix](#app1-dmso-5-227){ref-type="app"}). Medical studies provide very little information on the influence of parity on exercise tolerance, however, and this may be a promising new direction for physiological and pathophysiological research, particularly for developing countries.

### Other factors explaining the submaximal aerobic capacity decline

The aforementioned factors explain 58% of the total-sample 6MWD variability ([Table 3](#t3-dmso-5-227){ref-type="table"}), which means that 42% of the variability remains unexplained. What other factors not evaluated in the present study may affect the NIDDM patients' 6MWD?

As was said in the sixteenth century by Paracelsus (1493--1541), who wrote that "diabetes is a systemic disease caused by the presence of an abnormal product in the blood. This would act on the kidneys and cause polyuria,"[@b58-dmso-5-227] NIDDM can be considered a general disease with a metabolic starting point, the main pathophysiological mechanism being insulin resistance.[@b27-dmso-5-227] As part of this systemic disease, we can discuss the myopathy as an altering factor of the submaximal aerobic capacity.[@b41-dmso-5-227] This could be the result of numerous alterations, the main ones being inflammation,[@b35-dmso-5-227],[@b37-dmso-5-227],[@b39-dmso-5-227] apoptosis,[@b38-dmso-5-227] oxidative stress,[@b36-dmso-5-227] abnormal glucose and lipid or oxidative enzyme[@b59-dmso-5-227] metabolisms, abnormal microcirculation,[@b60-dmso-5-227] or abnormal type of fiber.[@b52-dmso-5-227] These factors are discussed in the [Appendix](#app1-dmso-5-227){ref-type="app"}.

In conclusion, NIDDM seems to accelerate the decline of the submaximal aerobic capacity evaluated through 6MWT data.
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Results
=======

Noninclusion criteria were found in 23 subjects: diabetes insulin-requiring (n = 15) or evolving less than 5 years (n = 4); nondiabetic subjects (n = 3); and type 1 diabetics (n = 1).

NIDDM PG: clinical, anthropometric and metabolic characteristics
================================================================

The median (first--third quartiles) of NIDDM evolution was 9 (7--12) years, and 93% of patients were treated by oral antidiabetic medication. The means ± SD of cigarette and narghile use were 20 ± 13 PY and 29 ± 41 NY, respectively. The mean ± SD of arterial hypertension evolution was 8 ± 6 years. All patients with a history of dyslipidemia, thyroid dysfunction, or diabetic retinopathy were treated. History of chronic respiratory diseases included tuberculosis (n = 5), asthma and/or atopy (n = 4), and obstructive sleep apnea (n = 1). History of chronic cardiovascular diseases included MI (n = 3), arrhythmia (n = 2), angina pectoris (n = 1), and arteritis of the lower extremities (n = 1). History of surgery included abdominopelvic (n = 22), thoracic (n = 2), and neurological (n = 1) surgery. Fifty percent and 20% of patients had low and high physical activity scores, respectively.

Comparison of NIDDM PG versus CG data
=====================================

Analysis of the total-sample data revealed the following points.

Compared to CG1, the PG had significantly higher quantities of used cigarettes and narghile; had a significantly higher percentage of cigarette and narghile users; had a significantly higher physical activity score, weight and BMI; had a significantly lower percentage of sedentary subjects or subjects with low SL, and was significantly younger. The 6MWD means (m, %) of PG with cigarette use ≤2 PY (n = 62, 547 ± 86 m, 95% ± 12%) or free from dyslipidemia (n = 33, 567 ± 75 m, 93% ± 11%) were significantly (*P* \< 0.05) lower than those of CG1 (n = 174, 636 ± 112 m, 100% ± 9%). 6MWD multiple regression analysis on CG1 shows that some variables were influencing factors only for the NIDDM PG, not the healthy CG1 (ie, obesity, SEL, cigarette use, and oxy-sat~rest~). This means that those factors were especially important for the NIDDM PG.

Compared to CG2, the PG had a significantly higher quantities of used cigarettes and narghile; had a significantly higher percentage of cigarette and narghile users; had a significantly higher physical activity score; had a significantly lower BMI and had a significantly lower percentage of sedentary or obese subjects or subjects having low-SE. Compared to CG2, the PG was significantly taller.

Compared to CG3, the PG had significantly higher quantities of used cigarettes and narghile; had significantly higher weight; had significantly higher percentage of subjects with surgery history; had a significantly lower BMI and had significantly lower percentages of obese patients or patients with chronic respiratory disease. Compared to CG3, the PG was significantly younger.

Discussion
==========

Study design (recruitment method, inclusion and noninclusion criteria, sample sizes, questionnaires)
----------------------------------------------------------------------------------------------------

Our cross-sectional study was economical, easy to apply, required less time than a longitudinal one, and provided more useful information.[@b61-dmso-5-227] In the present study, 6MWD values of NIDDM patients were compared with local 6MWD predicted norms,[@b62-dmso-5-227] and with measured 6MWD in three CGs.

As in any study on volunteers, there was possible bias in selection.[@b64-dmso-5-227] However, we limited this bias by the use of a medical questionnaire.[@b64-dmso-5-227]

Patients with NIDDM status for less than 5 years weren't included. It has been shown that NIDDM affects lung function only in the long term.[@b65-dmso-5-227] Patients aged under 40 were not included for two reasons: the average age of North African NIDDM patients is around 40 years,[@b66-dmso-5-227] and the 6MWD local norms were established in adults aged 40 and over.[@b62-dmso-5-227] To avoid potential confounding effects, we did not include patients with type 1 diabetes or with type 2 diabetes requiring insulin. As a precaution, 6MWT contraindications, which increase the risk of arrhythmia or collapse, were applied as noninclusion criteria.[@b67-dmso-5-227]

The sample size of the PG (n = 100) is less important than other studies related to the 6MWT of NIDDM patients, over the age of 68 years (n = 282)[@b68-dmso-5-227] or with heart failure (n = 256).[@b69-dmso-5-227] However, our sample size was calculated using a prediction equation.[@b70-dmso-5-227]

The physical activity questionnaire[@b71-dmso-5-227] -- interesting physical activities performed during the last 12 months -- is reproducible.

Precautions taken during 6MWT
=============================

NIDDM patients were told to continue their usual oral antidiabetic medication, since its use doesn't affect exercise tolerance.[@b72-dmso-5-227] Sources of variability caused by the procedure of the 6MWT itself were controlled as much as possible. Indeed, the 6MWT was performed as recommended in the open air in a corridor of 40 m length. A shorter corridor reduces 6MWD, since patients take longer to return.[@b62-dmso-5-227],[@b67-dmso-5-227] To minimize intraday variability and the effects of biological rhythms, the 6MWT were made in the morning (8 am to 10 am).[@b67-dmso-5-227] Similarly, we avoided encouragement known to increase 6MWD.[@b67-dmso-5-227]

Effect of parity
----------------

Effect of parity on the 6MWD can be explained by several hypotheses. First, hormonal alterations during pregnancy could generate aerobic system incapacity.[@b73-dmso-5-227] As the 6MWT solicits the aerobic system,[@b67-dmso-5-227] repeated gestations may accentuate or prolong this incapacity. Biochemical modifications were also suggested, since increased oxidative stress has been found during pregnancy.[@b74-dmso-5-227] With repeated gestations, the repeated oxidative stress could have negative effects on muscle function, explaining in part the 6MWD decline with high parity. Lastly, impaired respiratory muscle function is associated with high parity,[@b75-dmso-5-227] which may have influenced the ventilatory response in our subjects during exercise.

Other factors explaining the submaximal aerobic capacity decline
----------------------------------------------------------------

### Inflammation and apoptosis

It is now well known that NIDDM patients have systemic,[@b76-dmso-5-227] adipose tissue,[@b77-dmso-5-227] and muscle[@b78-dmso-5-227] inflammation. This inflammation degenerates muscle in several ways; for example by the activation of the ubiquitin--proteasome system[@b79-dmso-5-227] and stimulation of apoptosis.[@b80-dmso-5-227]

### Oxidative stress

The imbalance between pro-oxidants and antioxidants in favor of the former is an inseparable partner of inflammation. It is a factor in cell destruction, including muscle, but also induces changes in deoxyribonucleic acid.[@b81-dmso-5-227] In patients with NIDDM, oxidative stress, a consequence of a state of chronic hyperglycemia,[@b76-dmso-5-227] causes both a reduction in insulin secretion and decreases its action, adding to the state of insulin resistance. We believe that as in patients with chronic respiratory disease,[@b82-dmso-5-227] this oxidative stress increased significantly with overall exercise, resulting in muscle dysfunction.[@b82-dmso-5-227]

Abnormalities of glucose and lipid metabolism
---------------------------------------------

NIDDM results in morphological and functional abnormalities, including alterations in the hormonal system, enzymes, transport systems, use of energy substrates, and modulation of blood flow.[@b83-dmso-5-227] Indeed, it has been shown that the alteration in blood flow causes a reduction in the supply of glucose, which contributes to the decrease in total glucose uptake.[@b84-dmso-5-227] Abnormalities of glucose metabolism may also reflect alterations in the insulin receptor, such as a decrease in number or capacity for phosphorylation[@b85-dmso-5-227] and decreased translocation of glucose transporter insulin.[@b86-dmso-5-227] Phosphorylation of glucose-stimulated insulin is decreased as well as glycogen synthesis due to a defect in glucose uptake and reduced glycogen synthase activity.[@b87-dmso-5-227] Thus, muscle insulin--resistant patients are characterized by a decrease in oxidative enzyme activity, whereas the ability of anaerobic resynthesis of adenosine triphosphate is increased.[@b88-dmso-5-227] Similarly, there is a decrease in oxidative enzyme activity in the profits of glycolytic enzymes.[@b88-dmso-5-227] Thus, disturbances of carbohydrate metabolism can be summarized in a decrease in total glucose uptake, storage, and oxidation, and alterations in the insulin receptor.[@b89-dmso-5-227] NIDDM patients also have an alteration of lipid oxidation.[@b88-dmso-5-227] The rate of free fatty acids is increased in diabetics, but their availability and use by the muscle depends on capillarization and transport within the muscle cell, both of which are altered.[@b83-dmso-5-227],[@b89-dmso-5-227] For example, the activity of carnitine palmitoyl transferase is decreased in metabolic diseases and is negatively correlated with visceral adiposity.[@b83-dmso-5-227] Several other enzymatic mechanisms that allow the use of free fatty acids are also deficient as malate dehydrogenase and citrate synthase.[@b90-dmso-5-227]

Abnormalities of the microcirculation
-------------------------------------

Abnormalities of the microcirculation are represented by the decrease in local blood flow, the ability to recruit, and capillary density.[@b83-dmso-5-227] So there is less availability of energy substances.[@b83-dmso-5-227]

Abnormalities of muscle-fiber type
----------------------------------

Changes in muscle-fiber types are characterized by a decrease in oxidative type I fibers and increased type II fibers, less insulin sensitivity, and low endurance.[@b91-dmso-5-227] This results in a "deconditioning" of the peripheral muscles.

![The measured 6-minute walk distance (6MWD) of subgroups of non-insulin-dependent-diabetes mellitus males and females, according to age-group.\
**Notes:** Data are shown as box-and-whisker plots illustrating the mean ± standard deviation; *P*, comparison male versus female (paired *t*-test).\
**Abbreviation:** NS, not significant.](dmso-5-227f1){#f1-dmso-5-227}

###### 

Calculation of absolute cardiovascular disease risk[@b92-dmso-5-227]

                                                                                                                                                                                                                                                                                       Score
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------
  Age ≥ 50 years for males                                                                                                                                                                                                                                                             +1
  Age ≥ 60 years for females                                                                                                                                                                                                                                                           
  Family history of premature coronary heart disease: Myocardial infarction or sudden death \< 55 years with the father or a relative of first degree of male genderMyocardial infarction or sudden death \< 65 years with the mother or a relative of first degree of female gender   +1
  Current smoking or stopped less than 3 years                                                                                                                                                                                                                                         +1
  Treated or untreated permanent arterial hypertension                                                                                                                                                                                                                                 +1
  Presence of left ventricular hypertrophy                                                                                                                                                                                                                                             +1
  Treated or untreated non-insulin-dependent diabetes mellitus                                                                                                                                                                                                                         +1
  High-density lipoprotein cholesterol ≤ 1.0 mmol/L                                                                                                                                                                                                                                    +1
  High-density lipoprotein cholesterol ≥ 1.5 mmol/L                                                                                                                                                                                                                                    −1

###### 

Univariate analysis between 6-minute walk distance and the non-insulin-dependent diabetes mellitus patients' group data

                                                                                  Females (n = 45)                                       Males (n = 55)                                         Total sample (n = 100)
  ------------------------------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------
  **Smoking status, medical, surgical, and obstetric history**                                                                                                                                  
  Cigarette use                                                                                                                                                                                 
   Yes                                                                            Not done                                               595 ± 59                                               597 ± 59
   No                                                                                                                                    637 ± 75[\*](#tfn25-dmso-5-227){ref-type="table-fn"}   547 ± 86[\*](#tfn25-dmso-5-227){ref-type="table-fn"}
  Narghile use                                                                                                                                                                                  
   Yes                                                                            Not done                                               608 ± 69                                               616 ± 54
   No                                                                                                                                    616 ± 54                                               562 ± 81
  Chronic respiratory diseases                                                                                                                                                                  
   Yes                                                                            562 ± 31                                               588 ± 46                                               580 ± 42
   No                                                                             510 ± 64                                               612 ± 69                                               564 ± 84
  Arterial hypertension                                                                                                                                                                         
   Yes                                                                            521 ± 42                                               587 ± 53                                               551 ± 58
   No                                                                             507 ± 76                                               619 ± 71                                               574 ± 91
  Dyslipidemia                                                                                                                                                                                  
   Yes                                                                            514 ± 69                                               607 ± 86                                               554 ± 88
   No                                                                             513 ± 63                                               609 ± 65                                               568 ± 80
  Cardiovascular diseases                                                                                                                                                                       
   Yes                                                                            471 ± 96                                               571 ± 91                                               528 ± 100
   No                                                                             516 ± 61                                               612 ± 65                                               569 ± 79
  Dysthyroid                                                                                                                                                                                    
   Yes                                                                            537 ± 15                                               Not done                                               537 ± 15
   No                                                                             511 ± 66                                                                                                      567 ± 82
  Diabetic retinopathy                                                                                                                                                                          
   Yes                                                                            461 ± 101                                              577 ± 47                                               534 ± 88
   No                                                                             577 ± 60                                               612 ± 68                                               569 ± 80
  Surgical history                                                                                                                                                                              
   Yes                                                                            497 ± 69                                               595 ± 69                                               528 ± 82
   No                                                                             523 ± 52                                               611 ± 67                                               578 ± 25[\*](#tfn25-dmso-5-227){ref-type="table-fn"}
  Parity                                                                                                                                                                                        
   Low                                                                            528 ± 52                                                                                                      
   High                                                                           467 ± 74[\*](#tfn25-dmso-5-227){ref-type="table-fn"}                                                          
  **Medication use**                                                                                                                                                                            
  Beta-blocker use                                                                                                                                                                              
   Yes                                                                            491 ± 66                                               593 ± 43                                               532 ± 76
   No                                                                             517 ± 63                                               610 ± 69                                               570 ± 81
  Diuretic use                                                                                                                                                                                  
   Yes                                                                            551 ± 43                                               Not done                                               571 ± 54
   No                                                                             511 ± 64                                                                                                      566 ± 82
  **Socioeconomic, schooling, and physical activity levels**                                                                                                                                    
  Socioeconomic level                                                                                                                                                                           
   Low                                                                            497 ± 66                                               590 ± 50                                               520 ± 74
   High                                                                           539 ± 52[\*](#tfn25-dmso-5-227){ref-type="table-fn"}   613 ± 70                                               592 ± 73[\*](#tfn25-dmso-5-227){ref-type="table-fn"}
  Schooling level                                                                                                                                                                               
   Low                                                                            494 ± 65                                               601 ± 50                                               537 ± 80
   High                                                                           532 ± 56[\*](#tfn25-dmso-5-227){ref-type="table-fn"}   612 ± 73                                               583 ± 77[\*](#tfn25-dmso-5-227){ref-type="table-fn"}
  Physical activity level                                                                                                                                                                       
   Sedentary                                                                      502 ± 62                                               616 ± 71                                               543 ± 69
   Active                                                                         542 ± 59                                               605 ± 66                                               589 ± 69[\*](#tfn25-dmso-5-227){ref-type="table-fn"}
  **Metabolic characteristics**                                                                                                                                                                 
  Obesity                                                                                                                                                                                       
   Yes                                                                            511 ± 57                                               584 ± 47                                               537 ± 64
   No                                                                             518 ± 78                                               620 ± 72                                               592 ± 86[\*](#tfn25-dmso-5-227){ref-type="table-fn"}
  Uncontrolled diabetes                                                                                                                                                                         
   Yes                                                                            504 ± 74                                               606 ± 64                                               562 ± 85
   No                                                                             515 ± 47                                               613 ± 73                                               571 ± 75
  Measured dyslipidemia                                                                                                                                                                         
   Yes                                                                            511 ± 58                                               610 ± 76                                               565 ± 84
   No                                                                             519 ± 75                                               608 ± 47                                               567 ± 75
  **Anthropometric data and parity**                                                                                                                                                            
  Age (years)                                                                     −0.54[\*\*](#tfn26-dmso-5-227){ref-type="table-fn"}    −0.25[\*\*](#tfn26-dmso-5-227){ref-type="table-fn"}    −0,34[\*\*](#tfn26-dmso-5-227){ref-type="table-fn"}
  Weight (kg)                                                                     0.09                                                   −0.10                                                  0.03
  Height (m)                                                                      0.24                                                   0.20                                                   0.57[\*\*](#tfn26-dmso-5-227){ref-type="table-fn"}
  Body mass index (kg/m^2^)                                                       0.02                                                   −0.22                                                  −0.31[\*\*](#tfn26-dmso-5-227){ref-type="table-fn"}
  Parity (numerical)                                                              −0.44[\*\*](#tfn26-dmso-5-227){ref-type="table-fn"}                                                           
  **Metabolic data**                                                                                                                                                                            
  Fasting glycemia (mmol/L)                                                       0.05                                                   −0.03                                                  0.01
  Glycated hemoglobin (%)                                                         −0.16                                                  0.06                                                   0.01
  Triglycerides (mmol/L)                                                          −0.04                                                  0.09                                                   0.13
  Total cholesterol (mmol/L)                                                      0.01                                                   0.23                                                   0.01
  HDL-cholesterol (mmol/L)                                                        −0.08                                                  0.16                                                   0.03
  LDL-cholesterol (mmol/L)                                                        0.04                                                   0.09                                                   −0.09
  **Physical activity and absolute cardiovascular disease risk (ACVDR) scores**                                                                                                                 
  Activities                                                                                                                                                                                    
   Daily                                                                          −0.11                                                  0.02                                                   −0.36[\*\*](#tfn26-dmso-5-227){ref-type="table-fn"}
   Sporting                                                                       0.16                                                   −0.18                                                  0.19[\*\*](#tfn26-dmso-5-227){ref-type="table-fn"}
   Leisure                                                                        0.07                                                   0.28[\*\*](#tfn26-dmso-5-227){ref-type="table-fn"}     0.31[\*\*](#tfn26-dmso-5-227){ref-type="table-fn"}
   Physical                                                                       0.15                                                   −0.05                                                  0.24[\*\*](#tfn26-dmso-5-227){ref-type="table-fn"}
  ACVDR score                                                                     0.04                                                   −0.28[\*\*](#tfn26-dmso-5-227){ref-type="table-fn"}    0.21[\*\*](#tfn26-dmso-5-227){ref-type="table-fn"}
  **6MWT resting data**                                                                                                                                                                         
  Dyspnea (VAS)                                                                   0.23                                                   −0.21                                                  −0.05
  Heart rate (bpm)                                                                0.29[\*\*](#tfn26-dmso-5-227){ref-type="table-fn"}     −0.17                                                  −0.04
  Systolic pressure (mmHg)                                                        −0.04                                                  −0.30[\*\*](#tfn26-dmso-5-227){ref-type="table-fn"}    −0.20[\*\*](#tfn26-dmso-5-227){ref-type="table-fn"}
  Diastolic pressure (mmHg)                                                       0.25                                                   −0.21                                                  −0.01
  Oxy-sat (%)                                                                     0.18                                                   0.29[\*\*](#tfn26-dmso-5-227){ref-type="table-fn"}     0.21[\*\*](#tfn26-dmso-5-227){ref-type="table-fn"}

**Notes:** Data are expressed in means ± standard deviation;

*P* (probability, *t*-test) \< 0.05;

*P* (coefficient of correlation) \< 0.05.

**Abbreviations:** HDL, high-density lipoprotein; LDL, low-density lipoprotein; 6MWT, 6-minute walk test; VAS, visual analog scale; bpm, beats per minute; oxy-sat, oxyhemoglobin saturation.

###### 

Frequency in the present study and in the literature of risk factors and certain comorbidities in non-insulin-dependent diabetes mellitus[@b93-dmso-5-227]--[@b96-dmso-5-227]

                                   Frequency of the phenomenon in the present study   Prevalence of the phenomenon in the literature
  -------------------------------- -------------------------------------------------- ------------------------------------------------
  Smoking (cigarettes, narghile)   46                                                 64
  Sedentary status                 50                                                 38
  Low socioeconomic level          36                                                 38
  Obesity                          48                                                 52
  Dyslipidemia                     67                                                 50
  Arterial hypertension            37                                                 49
  Cardiovascular diseases          7                                                  25
  Chronic respiratory diseases     10                                                 4.7
  Diabetic retinopathy             8                                                  29
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###### 

Clinical, anthropometric, and metabolic characteristics of the non-insulin-dependent diabetes mellitus patient group

                                                                                                      Females (n = 45)   Males (n = 55)                                           Total sample (n = 100)
  --------------------------------------------------------------------------------------------------- ------------------ -------------------------------------------------------- ------------------------
  **Smoking status, medical, surgical and obstetric history, current medication (n)**                                                                                             
  Cigarette use                                                                                       1                  37[\*\*](#tfn3-dmso-5-227){ref-type="table-fn"}          38
  Narghile use                                                                                        0                  8[\*\*](#tfn3-dmso-5-227){ref-type="table-fn"}           8
  Chronic respiratory diseases                                                                        3                  7                                                        10
  Arterial hypertension                                                                               20                 17                                                       37
  Dyslipidemia                                                                                        8                  6                                                        14
  Cardiovascular diseases                                                                             3                  4                                                        7
  Dysthyroid                                                                                          4                  0[\*\*](#tfn3-dmso-5-227){ref-type="table-fn"}           4
  Diabetic retinopathy                                                                                3                  5                                                        8
  Renal failure                                                                                       0                  1                                                        1
  Anemia                                                                                              2                  1                                                        3
  Surgical history                                                                                    17                 8[\*\*](#tfn3-dmso-5-227){ref-type="table-fn"}           25
  Low parity                                                                                          34                                                                          
  Beta-blocker use                                                                                    6                  4                                                        10
  Diuretic use                                                                                        3                  1                                                        4
  Bronchodilator use                                                                                  2                  0                                                        2
  **Socioeconomic, schooling, and physical activity levels (n)**                                                                                                                  
  Low socioeconomic level                                                                             27                 9[\*\*](#tfn3-dmso-5-227){ref-type="table-fn"}           36
  Low schooling level                                                                                 22                 15[\*\*](#tfn3-dmso-5-227){ref-type="table-fn"}          37
  Sedentary status                                                                                    32                 18[\*\*](#tfn3-dmso-5-227){ref-type="table-fn"}          50
  **Daily, sporting, leisure, and physical activity scores, parity \[median (1st--3rd quartile)\]**                                                                               
  Activities                                                                                                                                                                      
   Daily                                                                                              2 (2--2)           1 (1--2)[\*](#tfn2-dmso-5-227){ref-type="table-fn"}      2 (1--2)
   Sporting                                                                                           2 (0--7)           8 (3--13)[\*](#tfn2-dmso-5-227){ref-type="table-fn"}     6 (1--11)
   Leisure                                                                                            1 (1--2)           2 (1--4)[\*](#tfn2-dmso-5-227){ref-type="table-fn"}      2 (1--3)
   Physical                                                                                           6 (4--11)          13 (7--18)[\*](#tfn2-dmso-5-227){ref-type="table-fn"}    9 (5--15)
  Parity (numerical)                                                                                  3 (2--4)                                                                    
  **Anthropometric data (mean ± SD)**                                                                                                                                             
  Age (years)                                                                                         55 ± 8             54 ± 8                                                   54 ± 8
  Weight (kg)                                                                                         80 ± 16            82 ± 11                                                  81 ± 14
  Height (m)                                                                                          1.56 ± 0.06        1.70 ± 0.06[\*](#tfn2-dmso-5-227){ref-type="table-fn"}   1.64 ± 0.09
  Body mass index (kg/m^2^)                                                                           33 ± 6             28 ± 4[\*](#tfn2-dmso-5-227){ref-type="table-fn"}        30 ± 5
  **Metabolic data and absolute cardiovascular disease risk (ACVDR) score (mean ± SD)**                                                                                           
  Fasting glycemia (mmol/L)                                                                           9.50 ± 3.24        9.47 ± 2.72                                              9.49 ± 2.95
  Glycated hemoglobin (%)                                                                             8 ± 2              8 ± 2                                                    8 ± 2
  Triglycerides (mmol/L)                                                                              1.47 ± 0.78        1.86 ± 1.50                                              1.68 ± 1.24
  Total cholesterol (mmol/L)                                                                          5.04 ± 1.01        4.78 ± 0.78                                              4.90 ± 0.89
  HDL-C (mmol/L)                                                                                      1.08 ± 0.30        1.06 ± 0.32                                              1.07 ± 0.31
  LDL-C (mmol/L)                                                                                      3.27 ± 0.92        2.87 ± 0.73[\*](#tfn2-dmso-5-227){ref-type="table-fn"}   3.05 ± 0.85
  ACVDR score                                                                                         2 ± 1              4 ± 1[\*](#tfn2-dmso-5-227){ref-type="table-fn"}         3 ± 1
  **Normal weight, overweight, and obese (number)**                                                                                                                               
  Normal weight                                                                                       5                  9                                                        14
  Overweight                                                                                          9                  29[\*\*](#tfn3-dmso-5-227){ref-type="table-fn"}          38
  Obese                                                                                                                                                                           
   Moderate                                                                                           16                 15                                                       31
   Marked                                                                                             10                 2[\*\*](#tfn3-dmso-5-227){ref-type="table-fn"}           12
   Extreme                                                                                            5                  0[\*\*](#tfn3-dmso-5-227){ref-type="table-fn"}           5
   Three degrees of obesity                                                                           31                 17[\*\*](#tfn3-dmso-5-227){ref-type="table-fn"}          48
  **Metabolic characteristics (number)**                                                                                                                                          
  Uncontrolled diabetes                                                                               25                 33                                                       58
  "Measured" dyslipidemia                                                                             30                 37                                                       67

**Notes:**

*P* (probability, *t*-test) \< 0.05, females vs males;

*P* (probability, chi-squared test) \< 0.05, females vs males.

**Abbreviations:** HDL-C, high-density-lipid cholesterol; LDL-C, low-density-lipid cholesterol.

###### 

Six-minute walk test (6MWT) data of the non-insulin-dependent diabetes mellitus patient group

                              Females (n = 45)   Males (n = 55)                                              Total sample (n = 100)                                                                                                                                                                                         
  --------------------------- ------------------ ----------------------------------------------------------- ---------------------------------------------------------------------------------------------- ----------------------------------------------------------- --------------------------------------------------- -----------------------------------------------------------
  Heart rate                                                                                                                                                                                                                                                                                                                
   (bpm)                      81 ± 12            118 ± 19[\#](#tfn7-dmso-5-227){ref-type="table-fn"}         78 ± 13                                                                                        113 ± 20[\#](#tfn7-dmso-5-227){ref-type="table-fn"}         79 ± 13                                             115 ± 19[\#](#tfn7-dmso-5-227){ref-type="table-fn"}
   (%)                        47 ± 7             69 ± 10[\#](#tfn7-dmso-5-227){ref-type="table-fn"}          46 ± 8                                                                                         67 ± 12[\#](#tfn7-dmso-5-227){ref-type="table-fn"}          46 ± 7                                              68 ± 11[\#](#tfn7-dmso-5-227){ref-type="table-fn"}
  6MWD                                                                                                                                                                                                                                                                                                                      
   (m)                        513 ± 63                                                                       609 ± 67[\*](#tfn6-dmso-5-227){ref-type="table-fn"}                                                                                                        566 ± 81                                            
   (%)                        98 ± 11                                                                        84 ± 9[\*](#tfn6-dmso-5-227){ref-type="table-fn"},[†](#tfn8-dmso-5-227){ref-type="table-fn"}                                                               90 ± 12[†](#tfn8-dmso-5-227){ref-type="table-fn"}   
  Oxy-sat (%)                 98 (97--98)        98 (97--98)                                                 98 (98--98)                                                                                    98 (97--98)[\#](#tfn7-dmso-5-227){ref-type="table-fn"}      98 (97--98)                                         98 (97--98)
  Systolic pressure (mmHg)    130 (120--140)     150 (140--160)[\#](#tfn7-dmso-5-227){ref-type="table-fn"}   130 (120--140)                                                                                 150 (130--160)[\#](#tfn7-dmso-5-227){ref-type="table-fn"}   130 (120--140)                                      150 (140--160)[\#](#tfn7-dmso-5-227){ref-type="table-fn"}
  Diastolic pressure (mmHg)   80 (80--80)        80 (80--90)[\#](#tfn7-dmso-5-227){ref-type="table-fn"}      80 (70--80)                                                                                    80 (80--90)[\#](#tfn7-dmso-5-227){ref-type="table-fn"}      80 (75--80)                                         80 (80--90)[\#](#tfn7-dmso-5-227){ref-type="table-fn"}
  Dyspnea (VAS)               0 (0--0)           2 (1--4)[\#](#tfn7-dmso-5-227){ref-type="table-fn"}         0 (0--0)                                                                                       2 (0--3)[\#](#tfn7-dmso-5-227){ref-type="table-fn"}         0 (0--0)                                            2 (1--3)[\#](#tfn7-dmso-5-227){ref-type="table-fn"}

**Notes:**

*P* (probability, *t*-test) \< 0.05, females vs males;

*P* (probability, *t*-test) \< 0.05, "rest vs end" 6MWT;

*P* (probability, *t*-test) \< 0.05, "measured vs theoretical" 6MWD; data are means for heart rate and 6MWD and medians (1st--3rd quartiles) for others.

**Abbreviations:** 6MWD, 6-minute walk distance; VAS, visual analog scale; bpm, beats per minute; oxy-sat, oxyhemoglobin saturation.

###### 

Independent variables included in the forward linear stepwise multiple regression model for the 6-minute walk distance (6MWD) of the non-insulin-dependent diabetes mellitus patient group

  Independent variables                                                        B         95% CI              Cumulative *r*^2^
  ---------------------------------------------------------------------------- --------- ------------------- -------------------
  **Females (n = 45)**                                                                                       
  Constant                                                                     714.54    630.01--799.07      
  Age (years)                                                                  −3.51     −5.12 to −1.90      0.297
  Socioeconomic level (0, low; 1, high)                                        29.44     2.79--56.09         0.382
  Parity (numerical)                                                           −6.09     −12.85--0.67        0.413
  **Males (n = 55)**                                                                                         
  Constant                                                                     −234.62   −1307.93--838.69    
  Systolic pressure~rest~ (mmHg)                                               −0.90     −2.03--0.24         0.091
  Leisure activity score                                                       8.88      3.40--14.36         0.166
  Cigarette use[\*](#tfn11-dmso-5-227){ref-type="table-fn"} (0, no; 1, yes)    −38.35    −65.73 to −10.98    0.234
  Oxy-sat~rest~ (%)                                                            10.90     0.24--1.56          0.292
  Physical activity score                                                      −1.80     −3.89--0.28         0.317
  Age (years)                                                                  −1.57     −3.39--0.26         0.344
  **Total sample (n = 100)**                                                                                 
  Constant                                                                     −105.48   −973.64--762.69     
  Gender (0, male; 1, female)                                                  −73.94    −101.23 to −46.65   0.350
  Age (years)                                                                  −3.25     −4.43 to −2.07      0.446
  Leisure activity score                                                       7.33      3.22--11.45         0.485
   Obesity[\*\*](#tfn12-dmso-5-227){ref-type="table-fn"} (0, no; 1, yes)       −35.57    −55.35 to −15.79    0.528
   Socioeconomic level (0, low; 1, high)                                       32.86     11.84--53.87        0.554
   Cigarette use[\*](#tfn11-dmso-5-227){ref-type="table-fn"} (0, no; 1, yes)   −27.67    −52.49 to −2.86     0.568
   Oxy-sat~rest~ (%)                                                           8.89      0.17--17.61         0.580

**Notes:** 95% CI, 95% confidence interval around each B;

cigarette use: 0, no (use ≤ 2 pack-years); 1, yes (use \> 2 pack-years);

obesity: 0, no (BMI \< 30 kg/m^2^); 1, yes (BMI ≥ 30 kgm^2^); proposed model for the NIDDM total sample: 6MWD (m) = −73.94 × gender (0, male, 1, female) − 3.25 × age (years) + 7.33 × leisure-activity score − 35.57 × obesity (0, no; 1, yes) + 32.86 × socioeconomic level (0, low; 1, high) − 27.67 × cigarette use (0, no; 1, yes) + 8.89 × oxy-sat~rest~ − 105.48.

**Abbreviation:** oxy-sat, oxyhemoglobin saturation.

###### 

Characteristics of non-insulin-dependent diabetes mellitus patients, divided according to their 6MWD (Group 1, abnormal 6MWD; Group 2: normal 6MWD)

                                                                                                                                                        Group 1 (n = 23)   Group 2 (n = 77)
  ----------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ ---------------------------------------------------------
  **Smoking, physical activity and absolute cardiovascular disease risk (ACVDR) scores, anthropometric, metabolic and resting 6MWT data (mean ± SD)**                      
  Cigarette use (pack-years)                                                                                                                            21 ± 13            19 ± 14
  Narghile use (narghile-years)                                                                                                                         26 ± 49            20 ± 28
  Age (years)                                                                                                                                           51 ± 6             55 ± 8[\*](#tfn15-dmso-5-227){ref-type="table-fn"}
  Weight (kg)                                                                                                                                           84 ± 12            80 ± 14
  Height (m)                                                                                                                                            1.69 ± 0.06        1.63 ± 0.09[\*](#tfn15-dmso-5-227){ref-type="table-fn"}
  Body mass index (kg/m^2^)                                                                                                                             30 ± 4             30 ± 5
  Glycated hemoglobin (%)                                                                                                                               7.75 ± 2.16        7.88 ± 2.12
  Fasting glycemia (mmol/L)                                                                                                                             9.69 ± 3.00        9.42 ± 2.95
  Triglycerides (mmol/L)                                                                                                                                2.00 ± 1.30        1.59 ± 1.21
  Total cholesterol (mmol/L)                                                                                                                            4.70 ± 0.73        4.96 ± 0.93
  HDL-C (mmol/L)                                                                                                                                        0.97 ± 0.20        1.10 ± 0.33
  LDL-C (mmol/L)                                                                                                                                        2.81 ± 0.83        3.12 ± 0.84
  Physical activity score                                                                                                                               13 ± 7             10 ± 6
  ACVDR score                                                                                                                                           4 ± 1              3 ± 1[\*](#tfn15-dmso-5-227){ref-type="table-fn"}
  Dyspnea (VAS)                                                                                                                                         0 ± 0              0 ± 0
  Heart rate (%)                                                                                                                                        46 ± 8             47 ± 7
  Systolic pressure (mmHg)                                                                                                                              129 ± 9            130 ± 14
  Diastolic pressure (mmHg)                                                                                                                             80 ± 6             79 ± 8
  Oxy-sat (%)                                                                                                                                           98 ± 1             98 ± 1
  6MWD                                                                                                                                                                     
   (m)                                                                                                                                                  544 ± 55           573 ± 86
   (%)                                                                                                                                                  76 ± 5             94 ± 10[\*](#tfn15-dmso-5-227){ref-type="table-fn"}
  **Percentage of patients with the following characteristics**                                                                                                            
  Cigarette use                                                                                                                                         83%                25%[\*\*](#tfn16-dmso-5-227){ref-type="table-fn"}
  Narghile use                                                                                                                                          17%                5%
  Chronic respiratory diseases                                                                                                                          4%                 12%
  Arterial hypertension                                                                                                                                 30%                39%
  Cardiovascular diseases                                                                                                                               13%                5%
  Diabetic retinopathy                                                                                                                                  7%                 8%
  Surgical history                                                                                                                                      17%                27%
  Beta-blocker use                                                                                                                                      0%                 13%
  Low socioeconomic level                                                                                                                               30%                38%
  Low schooling level                                                                                                                                   30%                39%
  Sedentary status                                                                                                                                      35%                55%
  Obesity                                                                                                                                               48%                48%
  Uncontrolled diabetes                                                                                                                                 57%                58%
  Dyslipidemia history                                                                                                                                  17%                13%
  "Measured" dyslipidemia                                                                                                                               87%                61%[\*\*](#tfn16-dmso-5-227){ref-type="table-fn"}

**Notes:**

*P* (probability, *t*-test) \< 0.05;

*P* (probability, chi-squared test) \< 0.05.

**Abbreviations:** 6MWD, 6-minute walk distance; 6MWT, 6-minute walk test; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VAS, visual analog scale; oxy-sat, oxyhemoglobin saturation.

###### 

Comparison of patient group (PG) data with those of three control groups (CG): CG1 (healthy nonobese and nonsmoking); CG2 (nondiabetic obese free from comorbidities); and CG3 ("all comers" -- nondiabetics)

                                                                  Females                                               Males                                                  Total sample                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  --------------------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------ ----------------------------------------------------- ------------------------------------------------------ ----------------------------------------------------- ------------------------------------------------------ ----------------------------------------------------- ------------------------------------------------------ ----------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------
  **Data are means ± standard deviation**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Cigarette use (PY)                                              2 ± 1[δ](#tfn22-dmso-5-227){ref-type="table-fn"}      0 ± 0[\*](#tfn19-dmso-5-227){ref-type="table-fn"}      0 ± 0[†](#tfn20-dmso-5-227){ref-type="table-fn"}      0 ± 0[\#](#tfn21-dmso-5-227){ref-type="table-fn"}      21 ± 13                                               0 ± 0[\*](#tfn19-dmso-5-227){ref-type="table-fn"}      0 ± 0[†](#tfn20-dmso-5-227){ref-type="table-fn"}      20 ± 22                                                20 ± 13                                               0 ± 0[\*](#tfn19-dmso-5-227){ref-type="table-fn"}       0 ± 0[†](#tfn20-dmso-5-227){ref-type="table-fn"}         13 ± 20
  Narghile use (NY)                                               0 ± 0                                                 0 ± 0                                                  0 ± 0                                                 0 ± 0                                                  23 ± 38[δ](#tfn22-dmso-5-227){ref-type="table-fn"}    0 ± 0[\*](#tfn19-dmso-5-227){ref-type="table-fn"}      0 ± 0[†](#tfn20-dmso-5-227){ref-type="table-fn"}      2 ± 8[\#](#tfn21-dmso-5-227){ref-type="table-fn"}      23 ± 38[δ](#tfn22-dmso-5-227){ref-type="table-fn"}    0 ± 0[\*](#tfn19-dmso-5-227){ref-type="table-fn"}       0 ± 0[†](#tfn20-dmso-5-227){ref-type="table-fn"}         1 ± 6[\#](#tfn21-dmso-5-227){ref-type="table-fn"}
  Physical-activity score                                         8 ± 5[δ](#tfn22-dmso-5-227){ref-type="table-fn"}      5 ± 4[\*](#tfn19-dmso-5-227){ref-type="table-fn"}      4 ± 2[†](#tfn20-dmso-5-227){ref-type="table-fn"}      Not done                                               13 ± 7[δ](#tfn22-dmso-5-227){ref-type="table-fn"}     7 ± 6[\*](#tfn19-dmso-5-227){ref-type="table-fn"}      7 ± 4[†](#tfn20-dmso-5-227){ref-type="table-fn"}      Not done                                               11 ± 7[δ](#tfn22-dmso-5-227){ref-type="table-fn"}     6 ± 5[\*](#tfn19-dmso-5-227){ref-type="table-fn"}       5 ± 3[†](#tfn20-dmso-5-227){ref-type="table-fn"}         Not done
  Age (years)                                                     55 ± 8[δ](#tfn22-dmso-5-227){ref-type="table-fn"}     56 ± 10                                                53 ± 10                                               61 ± 10[\#](#tfn21-dmso-5-227){ref-type="table-fn"}    54 ± 8                                                58 ± 11[\*](#tfn19-dmso-5-227){ref-type="table-fn"}    57 ± 11                                               56 ± 12                                                54 ± 8[δ](#tfn22-dmso-5-227){ref-type="table-fn"}     57 ± 10[\*](#tfn19-dmso-5-227){ref-type="table-fn"}     54 ± 10                                                  58 ± 12[\#](#tfn21-dmso-5-227){ref-type="table-fn"}
  Weight (kg)                                                     80 ± 16[δ](#tfn22-dmso-5-227){ref-type="table-fn"}    63 ± 8[\*](#tfn19-dmso-5-227){ref-type="table-fn"}     79 ± 6                                                80 ± 15                                                82 ± 11[δ](#tfn22-dmso-5-227){ref-type="table-fn"}    77 ± 9[\*](#tfn19-dmso-5-227){ref-type="table-fn"}     90 ± 9[†](#tfn20-dmso-5-227){ref-type="table-fn"}     92 ± 22[\#](#tfn21-dmso-5-227){ref-type="table-fn"}    81 ± 14[δ](#tfn22-dmso-5-227){ref-type="table-fn"}    70 ± 11[\*](#tfn19-dmso-5-227){ref-type="table-fn"}     82 ± 9                                                   87 ± 20[\#](#tfn21-dmso-5-227){ref-type="table-fn"}
  Height (m)                                                      1.56 ± 0.06                                           1.56 ± 0.07                                            1.57 ± 0.05                                           1.54 ± 0.06                                            1.70 ± 0.06                                           1.70 ± 0.06                                            1.68 ± 0.08                                           1.69 ± 0.07                                            1.64 ± 0.09                                           1.63 ± 0.10                                             1.61 ± 0.08[†](#tfn20-dmso-5-227){ref-type="table-fn"}   1.63 ± 0.10
  Body mass index (kg/m^2^)                                       33 ± 6[δ](#tfn22-dmso-5-227){ref-type="table-fn"}     26 ± 2[\*](#tfn19-dmso-5-227){ref-type="table-fn"}     32 ± 1                                                34 ± 6                                                 28 ± 4[δ](#tfn22-dmso-5-227){ref-type="table-fn"}     26 ± 2[\*](#tfn19-dmso-5-227){ref-type="table-fn"}     32 ± 1[†](#tfn20-dmso-5-227){ref-type="table-fn"}     32 ± 7[\#](#tfn21-dmso-5-227){ref-type="table-fn"}     30 ± 5[δ](#tfn22-dmso-5-227){ref-type="table-fn"}     26 ± 2[\*](#tfn19-dmso-5-227){ref-type="table-fn"}      32 ± 1[†](#tfn20-dmso-5-227){ref-type="table-fn"}        33 ± 6[\#](#tfn21-dmso-5-227){ref-type="table-fn"}
  Parity (numerical)                                              4 ± 2[δ](#tfn22-dmso-5-227){ref-type="table-fn"}      6 ± 3[\*](#tfn19-dmso-5-227){ref-type="table-fn"}      6 ± 2[†](#tfn20-dmso-5-227){ref-type="table-fn"}      5 ± 3[\#](#tfn21-dmso-5-227){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                       
  Dyspnea~rest~ (VAS)                                             0 ± 0                                                 0 ± 0                                                  0 ± 0                                                 0 ± 0                                                  0 ± 0[δ](#tfn22-dmso-5-227){ref-type="table-fn"}      0 ± 0                                                  0 ± 0                                                 1 ± 1[\#](#tfn21-dmso-5-227){ref-type="table-fn"}      0 ± 0[δ](#tfn22-dmso-5-227){ref-type="table-fn"}      0 ± 0                                                   0 ± 0                                                    0 ± 1[\#](#tfn21-dmso-5-227){ref-type="table-fn"}
  Dyspnea~end~ (VAS)                                              3 ± 2[δ](#tfn22-dmso-5-227){ref-type="table-fn"}      0 ± 0[\*](#tfn19-dmso-5-227){ref-type="table-fn"}      0 ± 0[†](#tfn20-dmso-5-227){ref-type="table-fn"}      5 ± 2[\#](#tfn21-dmso-5-227){ref-type="table-fn"}      2 ± 2[δ](#tfn22-dmso-5-227){ref-type="table-fn"}      0 ± 0[\*](#tfn19-dmso-5-227){ref-type="table-fn"}      0 ± 0[†](#tfn20-dmso-5-227){ref-type="table-fn"}      4 ± 2[\#](#tfn21-dmso-5-227){ref-type="table-fn"}      2 ± 2[δ](#tfn22-dmso-5-227){ref-type="table-fn"}      0 ± 0[\*](#tfn19-dmso-5-227){ref-type="table-fn"}       0 ± 0[†](#tfn20-dmso-5-227){ref-type="table-fn"}         4 ± 2[\#](#tfn21-dmso-5-227){ref-type="table-fn"}
  Heart rate~rest~ (%)                                            47 ± 7[δ](#tfn22-dmso-5-227){ref-type="table-fn"}     45 ± 5[\*](#tfn19-dmso-5-227){ref-type="table-fn"}     46 ± 6                                                50 ± 7                                                 46 ± 8                                                48 ± 6[\*](#tfn19-dmso-5-227){ref-type="table-fn"}     48 ± 6                                                47 ± 6                                                 46 ± 7                                                47 ± 6                                                  47 ± 6                                                   48 ± 7
  Heart rate~end~ (%)                                             69 ± 10                                               71 ± 9                                                 73 ± 10                                               68 ± 11                                                67 ± 12[δ](#tfn22-dmso-5-227){ref-type="table-fn"}    87 ± 11[\*](#tfn19-dmso-5-227){ref-type="table-fn"}    85 ± 12[†](#tfn20-dmso-5-227){ref-type="table-fn"}    73 ± 11[\#](#tfn21-dmso-5-227){ref-type="table-fn"}    68 ± 11[δ](#tfn22-dmso-5-227){ref-type="table-fn"}    79 ± 13[\*](#tfn19-dmso-5-227){ref-type="table-fn"}     77 ± 12[†](#tfn20-dmso-5-227){ref-type="table-fn"}       71 ± 11
  Systolic pressure~rest~ (mmHg)                                  131 ± 14[δ](#tfn22-dmso-5-227){ref-type="table-fn"}   123 ± 16[\*](#tfn19-dmso-5-227){ref-type="table-fn"}   126 ± 13                                              139 ± 29                                               129 ± 12                                              136 ± 22[\*](#tfn19-dmso-5-227){ref-type="table-fn"}   132 ± 16                                              136 ± 20[\#](#tfn21-dmso-5-227){ref-type="table-fn"}   130 ± 13[δ](#tfn22-dmso-5-227){ref-type="table-fn"}   130 ± 21                                                128 ± 14                                                 137 ± 24[\#](#tfn21-dmso-5-227){ref-type="table-fn"}
  Systolic pressure~end~ (mmHg)                                   150 ± 17[δ](#tfn22-dmso-5-227){ref-type="table-fn"}   152 ± 27                                               164 ± 25[†](#tfn20-dmso-5-227){ref-type="table-fn"}   165 ± 31[\#](#tfn21-dmso-5-227){ref-type="table-fn"}   147 ± 16[δ](#tfn22-dmso-5-227){ref-type="table-fn"}   176 ± 36[\*](#tfn19-dmso-5-227){ref-type="table-fn"}   178 ± 36[†](#tfn20-dmso-5-227){ref-type="table-fn"}   158 ± 37                                               148 ± 16[δ](#tfn22-dmso-5-227){ref-type="table-fn"}   164 ± 34[\*](#tfn19-dmso-5-227){ref-type="table-fn"}    168 ± 29[†](#tfn20-dmso-5-227){ref-type="table-fn"}      161 ± 35[\#](#tfn21-dmso-5-227){ref-type="table-fn"}
  Diastolic pressure~rest~ (mmHg)                                 80 ± 9[δ](#tfn22-dmso-5-227){ref-type="table-fn"}     72 ± 13[\*](#tfn19-dmso-5-227){ref-type="table-fn"}    76 ± 11                                               83 ± 19                                                79 ± 7                                                81 ± 16                                                76 ± 15                                               83 ± 11[\#](#tfn21-dmso-5-227){ref-type="table-fn"}    79 ± 8[δ](#tfn22-dmso-5-227){ref-type="table-fn"}     76 ± 15                                                 76 ± 13                                                  83 ± 14[\#](#tfn21-dmso-5-227){ref-type="table-fn"}
  Diastolic pressure~end~ (mmHg)                                  86 ± 12[δ](#tfn22-dmso-5-227){ref-type="table-fn"}    76 ± 13[\*](#tfn19-dmso-5-227){ref-type="table-fn"}    83 ± 11                                               91 ± 16                                                87 ± 9[δ](#tfn22-dmso-5-227){ref-type="table-fn"}     79 ± 20[\*](#tfn19-dmso-5-227){ref-type="table-fn"}    87 ± 26                                               91 ± 14                                                86 ± 11[δ](#tfn22-dmso-5-227){ref-type="table-fn"}    78 ± 17[\*](#tfn19-dmso-5-227){ref-type="table-fn"}     84 ± 17                                                  91 ± 15[\#](#tfn21-dmso-5-227){ref-type="table-fn"}
  Oxy-sat~rest~ (%)                                               98 ± 1[δ](#tfn22-dmso-5-227){ref-type="table-fn"}     98 ± 1                                                 97 ± 1[†](#tfn20-dmso-5-227){ref-type="table-fn"}     96 ± 2[\#](#tfn21-dmso-5-227){ref-type="table-fn"}     98 ± 1[δ](#tfn22-dmso-5-227){ref-type="table-fn"}     98 ± 1                                                 97 ± 1                                                96 ± 2[\#](#tfn21-dmso-5-227){ref-type="table-fn"}     98 ± 1[δ](#tfn22-dmso-5-227){ref-type="table-fn"}     98 ± 1                                                  97 ± 1[†](#tfn20-dmso-5-227){ref-type="table-fn"}        96 ± 2[\#](#tfn21-dmso-5-227){ref-type="table-fn"}
  Oxy-sat~end~ (%)                                                97 ± 2[δ](#tfn22-dmso-5-227){ref-type="table-fn"}     98 ± 1                                                 97 ± 2                                                94 ± 5[\#](#tfn21-dmso-5-227){ref-type="table-fn"}     97 ± 2[δ](#tfn22-dmso-5-227){ref-type="table-fn"}     97 ± 1                                                 97 ± 1                                                94 ± 6[\#](#tfn21-dmso-5-227){ref-type="table-fn"}     97 ± 2[δ](#tfn22-dmso-5-227){ref-type="table-fn"}     97 ± 1                                                  97 ± 1                                                   94 ± 5[\#](#tfn21-dmso-5-227){ref-type="table-fn"}
  6MWD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
   (m)                                                            513 ± 63[δ](#tfn22-dmso-5-227){ref-type="table-fn"}   556 ± 75[\*](#tfn19-dmso-5-227){ref-type="table-fn"}   538 ± 73                                              398 ± 98[\#](#tfn21-dmso-5-227){ref-type="table-fn"}   609 ± 67[δ](#tfn22-dmso-5-227){ref-type="table-fn"}   716 ± 82[\*](#tfn19-dmso-5-227){ref-type="table-fn"}   688 ± 72[†](#tfn20-dmso-5-227){ref-type="table-fn"}   572 ± 97[\#](#tfn21-dmso-5-227){ref-type="table-fn"}   566 ± 81[δ](#tfn22-dmso-5-227){ref-type="table-fn"}   636 ± 112[\*](#tfn19-dmso-5-227){ref-type="table-fn"}   585 ± 100                                                507 ± 129[\#](#tfn21-dmso-5-227){ref-type="table-fn"}
   (%)                                                            98 ± 11[δ](#tfn22-dmso-5-227){ref-type="table-fn"}    100 ± 10                                               100 ± 8                                               82 ± 18[\#](#tfn21-dmso-5-227){ref-type="table-fn"}    84 ± 9[δ](#tfn22-dmso-5-227){ref-type="table-fn"}     100 ± 8[\*](#tfn19-dmso-5-227){ref-type="table-fn"}    101 ± 7[†](#tfn20-dmso-5-227){ref-type="table-fn"}    83 ± 11                                                90 ± 12[δ](#tfn22-dmso-5-227){ref-type="table-fn"}    100 ± 9[\*](#tfn19-dmso-5-227){ref-type="table-fn"}     100 ± 8[†](#tfn20-dmso-5-227){ref-type="table-fn"}       83 ± 14[\#](#tfn21-dmso-5-227){ref-type="table-fn"}
  **Percentage of patients with the following characteristics**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Cigarette use                                                   2%                                                    0%                                                     0%                                                    0%                                                     67%                                                   0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}         0%[†](#tfn20-dmso-5-227){ref-type="table-fn"}         68%                                                    38%                                                   0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}          0%[†](#tfn20-dmso-5-227){ref-type="table-fn"}            42%
  Narghile use                                                    0%                                                    0%                                                     0%                                                    0%                                                     15%                                                   0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}         0%[†](#tfn20-dmso-5-227){ref-type="table-fn"}         16%                                                    8%                                                    0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}          0%[†](#tfn20-dmso-5-227){ref-type="table-fn"}            10%
  Chronic respiratory diseases                                    7%                                                    0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}         0%[†](#tfn20-dmso-5-227){ref-type="table-fn"}         82%[\#](#tfn21-dmso-5-227){ref-type="table-fn"}        13%                                                   0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}         0%                                                    63%[\#](#tfn21-dmso-5-227){ref-type="table-fn"}        10%                                                   0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}          0%[†](#tfn20-dmso-5-227){ref-type="table-fn"}            69%[\#](#tfn21-dmso-5-227){ref-type="table-fn"}
  Arterial hypertension                                           44%                                                   0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}         0%[†](#tfn20-dmso-5-227){ref-type="table-fn"}         41%                                                    31%                                                   0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}         0%[†](#tfn20-dmso-5-227){ref-type="table-fn"}         24%                                                    37%                                                   0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}          0%[†](#tfn20-dmso-5-227){ref-type="table-fn"}            31%
  Dyslipidemia history                                            18%                                                   0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}         0%[†](#tfn20-dmso-5-227){ref-type="table-fn"}                                                                11%                                                   0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}         0%                                                                                                           14%                                                   0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}          0%[†](#tfn20-dmso-5-227){ref-type="table-fn"}            
  Cardiovascular diseases                                         7%                                                    0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}         0%[†](#tfn20-dmso-5-227){ref-type="table-fn"}         14%                                                    7%                                                    0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}         0%                                                    16%                                                    7%                                                    0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}          0%[†](#tfn20-dmso-5-227){ref-type="table-fn"}            15%
  Surgery history                                                 38%                                                   0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}         0%[†](#tfn20-dmso-5-227){ref-type="table-fn"}         14%[\#](#tfn21-dmso-5-227){ref-type="table-fn"}        15%                                                   0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}         0%[†](#tfn20-dmso-5-227){ref-type="table-fn"}         3%[\#](#tfn21-dmso-5-227){ref-type="table-fn"}         25%                                                   0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}          0%[†](#tfn20-dmso-5-227){ref-type="table-fn"}            7%[\#](#tfn21-dmso-5-227){ref-type="table-fn"}
  Beta-blocker use                                                13%                                                   0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}         0%[†](#tfn20-dmso-5-227){ref-type="table-fn"}         18%                                                    7%                                                    0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}         0%                                                    5%                                                     10%                                                   0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}          0%[†](#tfn20-dmso-5-227){ref-type="table-fn"}            10%
  Low socioeconomic level                                         60%                                                   70%                                                    76%                                                   91%[\#](#tfn21-dmso-5-227){ref-type="table-fn"}        16%                                                   13%                                                    59%[†](#tfn20-dmso-5-227){ref-type="table-fn"}        19%                                                    36%                                                   41%                                                     71%[†](#tfn20-dmso-5-227){ref-type="table-fn"}           46%
  Low schooling level                                             49%                                                   70%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}        66%                                                   Not done                                               27%                                                   53%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}        12%                                                   Not done                                               37%                                                   61%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}         49%                                                      Not done
  Sedentary status                                                71%                                                   87%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}        95%[†](#tfn20-dmso-5-227){ref-type="table-fn"}        Not done                                               33%                                                   72%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}        71%[†](#tfn20-dmso-5-227){ref-type="table-fn"}        Not done                                               50%                                                   80%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}         87%[†](#tfn20-dmso-5-227){ref-type="table-fn"}           Not done
  Obesity                                                         69%                                                   0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}         100%[†](#tfn20-dmso-5-227){ref-type="table-fn"}       82%                                                    31%                                                   0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}         100%[†](#tfn20-dmso-5-227){ref-type="table-fn"}       68%[\#](#tfn21-dmso-5-227){ref-type="table-fn"}        48%                                                   0%[\*](#tfn19-dmso-5-227){ref-type="table-fn"}          100%[†](#tfn20-dmso-5-227){ref-type="table-fn"}          73%[\#](#tfn21-dmso-5-227){ref-type="table-fn"}

**Notes:**

*P* \< 0.05 (probability, *t*-test or chi-squared test), PG vs CG1;

*P* \< 0.05 (probability, *t*-test or chi-squared test), PG vs CG2;

*P* \< 0.05 (probability, *t*-test or chi-squared test), PG vs CG3;

analysis of variance.

**Abbreviations:** 6MWD, 6-minute walk distance; oxy-sat, oxyhemoglobin saturation; PY, pack-years: NY, narghile-years; VAS, visual analogue scale.
